Literature DB >> 8729879

The effector functions of immunoglobulins: implications for therapy.

E S Ward1, V Ghetie.   

Abstract

The effector functions of immunoglobulins of the G class (IgGs) are essential for their effective use in therapy. The functions that operate following complex formation with cognate antigen involve binding to C1q (to mediate complement fixation) and the Fc receptors, Fc gamma RI, II and III. Another class of functions that is independent of antigen binding encompasses the transfer of antibodies across the placenta and maintaining the levels in the serum. All effector functions of IgGs are conferred by sequences in the Fc region of antibodies, and this review discusses the localisation of the functions to specific amino acid residues. Such knowledge is of use for the further improvement of IgCs for therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8729879

Source DB:  PubMed          Journal:  Ther Immunol        ISSN: 0967-0149


  14 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Determining the phagocytic activity of clinical antibody samples.

Authors:  Elizabeth G McAndrew; Anne-Sophie Dugast; Anna F Licht; Justin R Eusebio; Galit Alter; Margaret E Ackerman
Journal:  J Vis Exp       Date:  2011-11-30       Impact factor: 1.355

Review 3.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

4.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

5.  Complement anaphylatoxin receptors C3aR and C5aR are required in the pathogenesis of experimental autoimmune uveitis.

Authors:  Lingjun Zhang; Brent A Bell; Minzhong Yu; Chi-Chao Chan; Neal S Peachey; John Fung; Xiaoming Zhang; Rachel R Caspi; Feng Lin
Journal:  J Leukoc Biol       Date:  2015-09-22       Impact factor: 4.962

6.  Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Authors:  Isaak Quast; Christian W Keller; Michael A Maurer; John P Giddens; Björn Tackenberg; Lai-Xi Wang; Christian Münz; Falk Nimmerjahn; Marinos C Dalakas; Jan D Lünemann
Journal:  J Clin Invest       Date:  2015-10-05       Impact factor: 14.808

Review 7.  An immunology primer for computational modelers.

Authors:  William F Hawse; Penelope A Morel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-09-20       Impact factor: 2.745

8.  A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.

Authors:  George W Buchman; Matthew E Cohen; Yuhong Xiao; Nicola Richardson-Harman; Peter Silvera; Louis J DeTolla; Heather L Davis; Roselyn J Eisenberg; Gary H Cohen; Stuart N Isaacs
Journal:  Vaccine       Date:  2010-07-24       Impact factor: 3.641

9.  Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes.

Authors:  Bruce D Wines; Amanda Gavin; Maree S Powell; Michael Steinitz; Russell R C Buchanan; P Mark Hogarth
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

10.  Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; John Laudenslager; Steven W Granger; Sandra Rickert; Lilia Koriazova; Tomoyuki Tahara; Ralph T Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.